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Abstract
Background: Human plasma and serum are widely used matrices in clinical and biological studies. However, different
collecting procedures and the coagulation cascade influence concentrations of both proteins and metabolites in these
matrices. The effects on metabolite concentration profiles have not been fully characterized.
Methodology/Principal Findings: We analyzed the concentrations of 163 metabolites in plasma and serum samples
collected simultaneously from 377 fasting individuals. To ensure data quality, 41 metabolites with low measurement
stability were excluded from further analysis. In addition, plasma and corresponding serum samples from 83 individuals
were re-measured in the same plates and mean correlation coefficients (r) of all metabolites between the duplicates were
0.83 and 0.80 in plasma and serum, respectively, indicating significantly better stability of plasma compared to serum
(p=0.01). Metabolite profiles from plasma and serum were clearly distinct with 104 metabolites showing significantly higher
concentrations in serum. In particular, 9 metabolites showed relative concentration differences larger than 20%. Despite
differences in absolute concentration between the two matrices, for most metabolites the overall correlation was high
(mean r=0.8160.10), which reflects a proportional change in concentration. Furthermore, when two groups of individuals
with different phenotypes were compared with each other using both matrices, more metabolites with significantly
different concentrations could be identified in serum than in plasma. For example, when 51 type 2 diabetes (T2D) patients
were compared with 326 non-T2D individuals, 15 more significantly different metabolites were found in serum, in addition
to the 25 common to both matrices.
Conclusions/Significance: Our study shows that reproducibility was good in both plasma and serum, and better in plasma.
Furthermore, as long as the same blood preparation procedure is used, either matrix should generate similar results in
clinical and biological studies. The higher metabolite concentrations in serum, however, make it possible to provide more
sensitive results in biomarker detection.
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Human plasma and serum are commonly used matrices in
biological and clinical studies. Serum is preferred in some assays
for cardiac troponins [1] whereas plasma is favored in oral glucose
tolerance tests for diabetes [2]. As reviewed by Mannello [3], use
of the wrong matrix (e.g. plasma in place of serum) can lead to
improper diagnosis. Both plasma and serum are derived from full
blood that has undergone different biochemical processes after
blood collection. Serum is obtained from blood that has
coagulated. Fibrin clots formed during coagulation, along with
blood cells and related coagulation factors, are separated from
serum by centrifugation. During this process, platelets release
proteins (e.g. proinflammatory cytokines [4]) and metabolites (e.g.
sphingosine-1-phosphate [5]) into the serum. To obtain plasma, an
anticoagulant like EDTA or heparin is added before the removal
of blood cells.
Several studies have examined the proteomic differences
between plasma and serum [6]. In the newly emerging field of
metabolomics [7–10], there were only a few recent studies related
to this subject (e.g. comparing different biofluids [11] or
comparing plasma and serum from animal blood [12]). Moreover,
two studies using small samples of around 15 human participants
addressed this issue with conflicting results. Teahan et al. [13]
reported minimal differences between the two matrices while Liu
et al. [14] observed changes ranging from 0.03 to 18-fold. Here,
we performed a targeted metabolomics study of 163 metabolites to
compare plasma and serum samples from 377 individuals. The
results showed a good reproducibility of metabolite concentrations
in both plasma and serum, although somewhat better in plasma.
There was also a clear discrimination between the metabolite
profiles of plasma and serum. Metabolite concentrations were
generally higher in serum, yet still highly correlated between the
two matrices. Furthermore, serum revealed more potential
biomarkers than plasma when comparing different phenotypes.
Results
We analyzed the concentrations of 122 metabolites in both
EDTA plasma and serum collected from 377 German participants
of the KORA (Cooperative Health Research in the Region of
Augsburg) F3 study [15,16]. These plasma and serum samples
were measured separately in 10 plates. In order to reduce potential
bias and authenticate our findings, measurements on samples from
83 randomly chosen KORA F3 participants were repeated in two
further plates, this time including both the plasma and the
corresponding serum sample from each person in the same plate
and all these samples were randomly distributed.
Good reproducibility in serum and better in plasma
Both plasma and serum displayed good stability in the
metabolite concentrations we measured. The metabolite concen-
trations from the repeated measurements on the 83 samples
showed a high correlation between the first and the second
measurements (Figure 1) with mean correlation coefficients (r)o f
all 122 metabolites being 0.83 and 0.80 for plasma and serum,
respectively. Thus, reproducibility was significantly better for
plasma than for serum (p=0.01, paired t-test), although the
absolute differences in r were small.
High correlation between plasma and serum metabolite
concentrations and higher concentrations in serum
Altogether, plasma and serum samples from 83 individuals were
measured in the same plates. Results showed that metabolite
concentrations were generally higher in serum than in plasma
(Figure 2). Out of 122 metabolites, 104 (85%) were significantly
higher in serum and the average value of the relative difference
over all metabolites was 11.7% higher in serum. A partial least
squares (PLS) analysis of 377 KORA individuals also demonstrat-
ed that plasma samples were clearly separated from serum samples
(Figure 3). In addition, we observed an overall high correlation
Figure 1. Correlation between repeated measurements of plasma and serum metabolites. Correlation coefficients (r) between repeated
measurements of metabolite concentrations were plotted. r values in serum are plotted against r values in plasma. Shapes represent different groups
of metabolites: Acylcarnitines (N), Amino acids (m), Hexose (+), and Glycerophospholipid (&). Colors represent different subgroups of
glycerophospholipids: lysoPhosphatidylcholine (blue), Phosphatidylcholine (red), and Sphingomyeline (green).
doi:10.1371/journal.pone.0021230.g001
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indicating that differences of metabolite concentrations between
both matrices are due to systematic changes across all individuals.
This is especially true for most acylcarnitines (mean r=0.8660.09)
and glycerophospholipids (mean r=0.8260.09). However, for
amino acids, the correlation between the two matrices was
significantly lower (mean r=0.6760.13) compared to all the
metabolites (p=0.004, t-test) (Figure 2).
Among the metabolites with significantly higher concentrations
in serum, 9 metabolites had relative concentration differences
greater than 20% (Figure 2). Arginine had the highest concentra-
tion difference, displaying a nearly 50% higher concentration in
serum with a lower correlation (r=0.50) between the two matrices,
while diacyl-phosphatidylcholine C38:1, which was 26% higher in
serum than in plasma, still kept a good correlation (r=0.88). Four
lyso-phosphatidylcholines (C16:0, C17:0, C18:0, C18:1) and three
other amino acids (serine, phenylalanine, glycine) were also found
to have more than 20% higher concentrations in serum.
Higher sensitivity in serum
We also noticed that serum provided higher sensitivity than
plasma, when average metabolite concentrations were compared
between subjects with different phenotypes. For example, 40
metabolites in serum were identified to have a significantly
different mean concentration in type 2 diabetes (T2D) patients vs.
non-T2D individuals, while plasma only revealed 25. Similar
results were also observed when comparing male against female
individuals, as well as when comparing smokers against non-
smokers, serum always containing larger number of significantly
Figure 2. Relative concentration differences and correlation coefficients between plasma and serum for individual metabolites. The
X-axis indicates the mean value of the relative concentration difference. Shapes represent different groups of metabolites: Acylcarnitines (N), Amino
acids (m), Hexose (+), and Glycerophospholipid (&). Colors represent different subgroups of glycerophospholipids: lysoPhosphatidylcholine (blue),
Phosphatidylcholine (red), and Sphingomyeline (green). Metabolite names are indicated for metabolites with a mean relative concentration
difference larger than 15%. (A) 199 original individuals (B) one plate of repeated measurements from 44 individuals.
doi:10.1371/journal.pone.0021230.g002
Figure 3. Separation of plasma and serum metabolite profiles.
Results of the partial least squares (PLS) analysis. Scores of the first two
PLS components were plotted against each other. Each point indicates
either a plasma (red) or serum (blue) sample.
doi:10.1371/journal.pone.0021230.g003
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phenotypes, all significantly different metabolites that were
identified using plasma were among those identified using serum.
The metabolites that failed to be identified in plasma were,
nevertheless, close to the borderline of significance.
Discussion
The present study provides a robust analysis based on a large
size sample and highly reliable measurements of metabolites with
stringent quality controls. The method has been proven to be in
conformance with the FDA-Guideline ‘‘Guidance for Industry -
Bioanalytical Method Validation (May 2001)’’, which implies
proof of reproducibility within a given error range. Our results
give support of good reproducibility of metabolite measurements
in both plasma and serum. Moreover, plasma demonstrates a
better reproducibility than serum, which may result from the less
complicated collecting procedure for plasma, as it does not require
time to coagulate. The large sample size is not only powerful
enough to detect metabolite concentration differences between the
two matrices but also makes possible the further characterization
of the relationship between them.
We observed that metabolite concentrations were generally
higher in serum and this phenomenon may partly be explained by
the volume displacement effect [17], which means that deprotein-
ization of serum eliminates the volume fraction of proteins and
distributes the remaining small molecular weight constituents in a
smaller volume, thus making them more concentrated.
Concentration differences in some metabolites were similar to
those observed in previous studies and some differences were
related to coagulation processes. The higher arginine concentra-
tion in serum has been reported before by Teerlink et al. [18]. The
release of arginine from platelets during the coagulation process
might account for this difference.
Our observations that concentrations of some LPCs were higher
in serum are consistent with a former study by Aoki et al. [19],
who reported increased LPC concentrations, due to release of
phospholipases by platelets activated by thrombin, a process that
also occurs upon coagulation.
Glucose, which represents the majority of hexose, was found in
an earlier study [20] to be 5% lower in plasma than in serum. A
similar difference was observed for hexose in our measurements.
Although the exact reason for this observation is not clear, a shift
in fluid from erythrocytes to plasma caused by anticoagulants
might play a role [2].
Serum demonstrated a higher sensitivity in biomarker detection.
The generally higher metabolite concentrations in serum than in
plasma might lead to this advantage. Metabolite measurements in
both matrices are subject to a certain level of background noise,
which might affect measurement accuracy, especially for metab-
olites with low concentrations. Thus plasma is more prone to this
effect than serum, where metabolite concentrations are generally
higher. It was also proposed that the lower protein content in
serum might benefit small molecule analyses and improve overall
sensitivity [21]. However, in our comparisons, the metabolites that
differed significantly between two phenotypes in serum but not in
plasma are, nevertheless, close to the significance level when
plasma was used, an observation that is in agreement with the
existence of high correlations between both matrices.
The high correlations between plasma and serum measure-
ments suggest that the shift in metabolite concentrations per se
does not necessarily introduce a bias in epidemiological studies,
although the higher concentrations in serum may provide some
advantages. In general, our data indicate that metabolite profiles
from either matrix can be analyzed, as long as the same blood
sample is used. However, the better reproducibility in plasma and
higher sensitivity need to be taken into account, as they might
influence the results for the identification of diagnostic biomarkers.
Naturally, the metabolites we measured in our experiment
represent only a small part of the human blood metabolome.
Accordingly, it is yet to be determined in future studies whether
similar observations can be made for other metabolites.
Materials and Methods
We obtained written informed consent from all participants and
approval from the local ethical committee.
KORA is a population-based research platform with subsequent
follow-up studies in the fields of epidemiology, health economics
and health care research [15]. It is based on interviews in
combination with medical and laboratory examinations, as well as
the collection of biological samples.
Plasma and serum from 377 individuals (180 female, 197 male,
age range from 51 to 84 years) from the population based cohort
KORA F3 [22] were used in this study. For each participant,
fasting blood was simultaneously drawn into serum and EDTA
plasma gel tubes between 8 and 10 am. Plasma tubes were shaken
gently and thoroughly for 15 minutes followed by centrifugation at
2750 g for 15 minutes at 15uC. In the meantime, serum tubes
were gently inverted twice followed by 45 minutes resting at room
temperature to obtain complete coagulation, before performing
the same centrifugation process as for plasma. All samples were
stored at -80uC until the metabolic analyses.
In total, 26 quantified and 137 semi-quantified (due to the lack
of standards) metabolites were measured in 377 plasma and serum
samples using a commercially available metabolomics kit (Abso-
luteIDQ
TM kit p150, Biocrates Life Sciences AG, Innsbruck,
Austria) based on FIA-MS. The assay procedures and the full
biochemical names have been described in more detail in our
previous work [8,23–25] and the analytical details have been
reviewed and compared with other analytical technology [26].
The first measurement of 377 plasma and serum samples took
place in two separate batches, with a three months time interval in
between. Each batch contained 5 plates. To ensure the detection
of true effects, measurements on samples from 83 randomly
chosen KORA F3 participants from all 5 plates were repeated on
two additional plates (39 and 44 samples, respectively), with both
the plasma and the corresponding serum samples from the same
person being measured in the same plates and samples randomly
distributed in the plates.
To control data quality, a metabolite had to meet three criteria:
(I) the average value of the coefficient of variance of the three
quality control samples (representing human plasma samples
Table 1. Numbers of significant different metabolite in
plasma and serum.
Plasma (n=377) Serum (n=377)
T2D vs. non-T2D (51 vs. 326) 25 40
Male vs. Female (197 vs. 180) 62 69
Smoker vs. non-smoker (45 vs. 332) 4 6
All three analyses use both plasma and serum from the same individuals. In
each analysis, two different phenotypes were compared using a Wilcoxon test
with the Bonferroni correction. The numbers of significantly different
metabolites between phenotypes are shown in the table.
doi:10.1371/journal.pone.0021230.t001
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than 0.25; (II) the mean concentration of the metabolite over all
samples should be above 0.1 mM or the metabolite concentration
should be above the limit of detection (LOD) for 90% of the
samples. The LODs were set to three times the values of zero
samples (e.g. extraction solution or PBS with internal standards);
(III) the correlation coefficient between the 83 repeated measure-
ments in either specimen must exceed 0.5. Altogether, 25
quantified and 97 semi-quantified metabolites passed both criteria
(Table S1).
In order to detect real differences between plasma and serum
rather than the differences between plates, a plate correction factor
was calculated for each plate using the plate containing re-
measured samples from 39 individuals as a basis: the geometric
mean was taken for each pair of metabolite concentrations
determined from the repeated measurements on 39 plasma and 39
serum samples and divided by the concentration determined in the
respective plate, yielding 78 ratios per metabolite. Subsequently,
for each of the 10 original plates, the geometric mean of all the
ratios was calculated and used as plate-specific correction factors.
Partial least squares (PLS) was performed using scaled
metabolite concentrations to investigate a possible separation of
metabolite profiles between plasma and serum samples. For each
metabolite, the Pearson’s correlation coefficient (r) was calculated,
and a paired Wilcoxon test was performed to compare metabolite
concentrations in plasma vs. serum. In addition, to calculate the
relative concentration differences, we divided the absolute
concentration difference (serum minus plasma) of each metabolite
by its average concentration over the two matrices.
Three analyses were performed to compare metabolite
concentrations in (I) diabetes patients vs. normal individuals, (II)
male vs. female individuals and (III) smokers vs. non-smokers using
both plasma and serum samples. The group of diabetes patients
included self-reported cases and subjects reported to take diabetic
medications. In all three analyses, we used a Wilcoxon test to find
metabolites that are significantly different between the respective
groups and the same procedures were applied to both plasma and
serum samples. In all the three analyses mentioned above,
different phenotypes were randomly distributed among plates.
All calculations were performed under the R statistical
environment (http://www.r-project.org/).
Supporting Information
Table S1 Summary of metabolites in plasma and serum
samples.
(XLS)
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